A Service For Professionals Monday, December 11, 2017
Contact (202) 540-8337
Company News Today
A Service For Professionals Monday, December 11, 2017 11614 Sources 420,542,233 Articles 2,875,095 Readers
Contact (202) 540-8337

Natus Medical Announces Second Quarter 2017 Financial Results

  • Reports record second quarter 2017 revenue of $122.2 million
  • Reports second quarter GAAP earnings (loss) per share of ($0.15) and non-GAAP of $0.34 per share

PLEASANTON, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Natus Medical Incorporated (NASDAQ:BABY) today announced financial results for the three months ended June 30, 2017.

For the second quarter ended June 30, 2017, the Company reported revenue of $122.2 million, an increase of 27.3% compared to $96.0 million reported for the second quarter 2016. GAAP gross profit margin was 54.1% vs. 59.9% reported for the second quarter 2016. GAAP net loss was $5.0 million, or $(0.15) per diluted share, compared with GAAP net income of $10.5 million, or $0.32 per diluted share in the second quarter 2016.

Non-GAAP earnings per diluted share was $0.34 for the second quarter 2017, compared to $0.39 in the second quarter 2016. Non-GAAP net income was $11.2 million for the second quarter 2017 compared to the prior year's second quarter non-GAAP net income of $12.8 million. Non-GAAP gross profit margin was 60.6% vs. 60.5% reported for the second quarter of 2016. 

For the six months ended June 30, 2017, the Company reported revenue of $246.9 million, an increase of 34.7% compared to $183.3 million reported for the same period in 2016. GAAP Gross profit margin was 53.8% vs. 61.0% reported for the same period in 2016. GAAP net loss was $4.7 million, or $(0.14) per diluted share, compared with GAAP net income of $19.1 million, or $0.58 per diluted share in the same period in 2016.

Non-GAAP earnings per diluted share was $0.64 for the first six months in 2017, compared to $0.72 in the same period in 2016. The Company reported non-GAAP net income of $21.0 million for the six months ended June 30, 2017, compared to the prior year's non-GAAP net income of $23.9 million.

The Company repurchased $1.0 million of its stock during the second quarter of 2017 and repaid $40.0 million in outstanding debt.

"I am very pleased with our record second quarter revenues and our non-GAAP earnings that exceeded the high-end of our guidance.  Recently acquired Otometrics had another strong quarter and is ahead of our goal to achieve 10% non-GAAP operating margins for 2017.  I am also pleased that we achieved year-over-year revenue growth in our international neurodiagnostic business.  This segment had been under pressure in recent years due to a combination of soft international markets and the strong dollar.  We are hopeful these headwinds are now behind us," said Jim Hawkins, President and Chief Executive Officer of the Company.

"At our recent Analyst Day, we unveiled Otoscan, Otometric's revolutionary hearing aid fitting product.  Otoscan looks to digitize the hearing aid fitting process from the initial hearing aid fitting, to the manufacturer, and to the customer.  We anticipate the introduction of Otoscan in our first quarter 2018.  Otoscan represents a large opportunity for Natus in the growing worldwide hearing aid fitting market," Hawkins continued.

Financial Guidance

For the third quarter of 2017, the Company provided revenue guidance of $121.0 million to $123.0 million and non-GAAP earnings per share guidance of $0.37 to $0.38.

For the full year 2017, the Company maintained revenue guidance of $505.0 million to $510.0 million and maintained its non-GAAP earnings per share to $1.70 to $1.75.

The Company's non-GAAP earnings per share guidance excludes charges for amortization expense associated with intangible assets from prior acquisitions, which the Company expects to be approximately $5.7 million and $22.8 million for the third quarter 2017 and full year, respectively, and which the Company expects will reduce GAAP earnings per share by approximately $0.17 and $0.69 for the respective periods.  Non-GAAP earnings per share also excludes the direct and transition costs of the Otometrics acquisition, which are estimated to be approximately $3 million to $4 million for the full year 2017 excluding the inventory FMV step-up of $4.4 million required for purchase accounting.

Use of Non-GAAP Financial Measures

The Company presents in this release its non-GAAP net income, non-GAAP earnings per share, non-GAAP gross margin and non-GAAP operating margin results which exclude amortization expense associated with certain acquisition-related intangibles, restructuring charges, certain discrete items, direct costs of acquisitions, and the related tax effects. A reconciliation between non-GAAP and GAAP financial measures is included in this press release.

The Company believes that the presentation of results excluding these charges or gains provides meaningful supplemental information to both management and investors that is indicative of the Company's core operating results and better reflects the ongoing economics of the Company's operations. The Company believes these non-GAAP financial measures facilitate comparison of operating results across reporting periods.

Specifically, the Company excludes the following charges, gains, and their related tax effects in the calculation of non-GAAP net income, non-GAAP earnings per share and non-GAAP operating expense and excludes all but restructuring charges from the calculation of non-GAAP gross margin: 1) Non-cash amortization expense associated with certain acquisition-related intangibles. The charges reflect an estimate of the cost of acquired intangible assets over their estimated useful lives. 2) Restructuring charges. The Company has over time completed multiple acquisitions of other companies and businesses. Following an acquisition the Company will, as it determines appropriate, initiate restructuring events to eliminate redundant costs. Restructuring expenses, which are excluded in the non-GAAP items, are exclusively related to permanent reductions in our workforce and redundant facility closures. 3) Certain discreet items. These items represent significant infrequent charges or gains that management believes should be viewed outside of normal operating results. These items are specifically identified when they occur. 4) Direct costs of acquisitions.  These are direct acquisition-related costs that occur when the Company makes an acquisition, such as professional fees, due diligence costs, and earn-out adjustments.

/EIN News/ -- The Company applies GAAP methodologies in computing its non-GAAP tax provision by determining the annual expected effective tax rate after taking into account items excluded for non-GAAP financial reporting purposes.  The Company’s non-GAAP tax expense and its non-GAAP effective tax rate are generally higher than its GAAP tax expense and GAAP effective tax rate because the income subject to taxes would be higher due to the effect of the expenses excluded from non-GAAP financial reporting. The nature of each quarterly discrete transaction will be evaluated to determine whether it should be excluded from non-GAAP reporting.

The Company's management uses these non-GAAP financial measures in assessing the Company's performance and when planning, forecasting, and analyzing future periods and the Company believes that investors also benefit from being able to refer to these non-GAAP financial measures along with the GAAP operating results. These non-GAAP financial measures also facilitate management's internal comparisons to the Company's historical performance. The non-GAAP financial measures disclosed by the Company should not be considered a substitute for or superior to financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated.

Conference Call

Natus has scheduled an investment-community conference call to discuss this announcement beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) today, July 26, 2017. Individuals interested in listening to the conference call may do so by dialing 1-844-634-1441 for domestic callers, or 1-508-637-5658 for international callers, and entering reservation code 55329407. A telephone replay will be available for 48 hours following the conclusion of the call by dialing 1-855-859-2056 for domestic callers, or 1-404-537-3406 for international callers, and entering reservation code 55329407. The conference call also will be available real-time via the Internet at http://investor.natus.com, and a recording of the call will be available on the Company’s Web site for 90 days following the completion of the call.

About Natus Medical Incorporated

Natus is a leading provider of healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments in neurological dysfunction, epilepsy, sleep disorders, newborn care, hearing impairment and balance and mobility disorders.

Additional information about Natus Medical can be found at www.natus.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, particularly statements regarding the expectations, beliefs, plans, intentions and strategies of Natus. These forward-looking statements include statements regarding Otometrics revenue growth rate, increasing the profitability of Otometrics, the anticipated revenue and GAAP and non-GAAP earnings per share for the third quarter and full year 2017 and the impact of amortization expense associated with acquisition-related intangible assets. These statements relate to current estimates and assumptions of our management as of the date of this press release and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements are only predictions and the actual events or results may differ materially. Natus cannot provide any assurance that its future results or the results implied by the forward-looking statements will meet expectations. Our future results could differ materially due to a number of factors, including the effects of competition, our ability to successfully integrate the Otometrics acquisition and achieve our profitability goals for Otometrics, the demand for our products and services, the impact of adverse global economic conditions and changing governmental regulations, including foreign exchange rate changes,  on our target markets, our ability to expand our sales in international markets, our ability to maintain current sales levels in a mature domestic market, our ability to control costs, risks associated with bringing new products to market and integrating acquired businesses, shipments and revenue associated with our Medix subsidiary's contract with the Venezuela Ministry of Health and our ability to fulfill product orders on a timely basis. Natus disclaims any obligation to update information contained in any forward looking statement.

More information about potential risk factors that could affect the business and financial results of Natus is included in Natus' annual report on Form 10-K for the year ended December 31, 2016, and its subsequent quarterly reports on Form 10-Q and in other reports filed from time to time by Natus with the U.S. Securities and Exchange Commission.

NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (unaudited)
(in thousands, except per share amounts)
               
   Quarter Ended    Year to Date
  June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016
Revenue $ 122,227     $ 95,958     $ 246,887     $ 183,287  
Cost of revenue 54,589     37,879     111,503     70,348  
Intangibles amortization 1,500     604     2,500     1,205  
  Gross profit 66,138     57,475     132,884     111,734  
Gross profit margin 54.1 %   59.9 %   53.8 %   61.0 %
Operating expenses:              
  Marketing and selling 30,354     21,237     62,569     41,831  
  Research and development 13,713     7,105     26,466     14,907  
  General and administrative 24,156     11,923     40,172     24,404  
  Intangibles amortization 3,885     2,197     7,959     4,332  
  Restructuring 307     1,083     593     1,118  
  Total operating expenses 72,415     43,545     137,759     86,592  
Income (loss) from operations (6,277 )   13,930     (4,875 )   25,142  
Interest expense (1,281 )   (92 )   (2,261 )   (110 )
Other income/(expense), net 903     117     843     591  
Income (loss) before tax (6,655 )   13,955     (6,293 )   25,623  
Provision for income tax expense (benefit) (1,621 )   3,443     (1,606 )   6,573  
Net (loss) income $ (5,034 )   $ 10,512     $ (4,687 )   $ 19,050  
Earnings (loss) per share:              
  Basic $ (0.15 )   $ 0.32     $ (0.14 )   $ 0.59  
  Diluted $ (0.15 )   $ 0.32     $ (0.14 )   $ 0.58  
Weighted-average shares:              
  Basic 32,529     32,438     32,507     32,521  
  Diluted 33,034     32,983     33,061     33,118  


NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (unaudited)
(in thousands)
           
  June 30,   March 31,   December 31,
  2017   2017   2016
ASSETS          
           
Current assets:          
Cash and investments $ 80,303     $ 112,862     $ 247,570  
Accounts receivable, net 114,063     114,386     86,638  
Inventories 69,278     67,684     49,587  
Other current assets 23,340     21,539     22,004  
Total current assets 286,984     316,471     405,799  
           
Property and equipment, net 20,853     20,896     17,333  
Goodwill and intangible assets 320,824     316,639     190,277  
Deferred income tax 14,714     14,678     14,915  
Other assets 19,211     20,171     20,688  
Total assets $ 662,586     $ 688,855     $ 649,012  
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current liabilities:          
Accounts payable $ 26,762     $ 26,073     $ 18,700  
Accrued liabilities 44,662     44,652     37,895  
Deferred revenue 14,813     14,811     23,346  
Total current liabilities 86,237     85,536     79,941  
           
Long-term liabilities:          
Long-term debt, net 109,498     149,889     140,000  
Deferred income tax 31,037     24,811     3,684  
Other long-term liabilities 9,323     8,208     8,013  
Total liabilities 236,095     268,444     231,638  
Total stockholders’ equity 426,491     420,411     417,374  
Total liabilities and stockholders’ equity $ 662,586     $ 688,855     $ 649,012  


NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(in thousands)
   
   Quarter Ended
  June 30, 2017   June 30, 2016
Operating activities:      
Net income (loss) $ (5,034 )   $ 10,512  
Adjustments to reconcile net income (loss) to net cash provided by operating activities:      
Provision for losses on accounts receivable 5,353     408  
Depreciation and amortization 7,075     4,173  
Loss on disposal of property and equipment (11 )   (46 )
Warranty reserve 2,902     1,383  
Share-based compensation 2,219     2,102  
Changes in operating assets and liabilities:      
Accounts receivable (6,532 )   (2,672 )
Inventories 1,470     1,255  
Prepaid expenses and other assets (1,709 )   (1,778 )
Accounts payable 352     (896 )
Accrued liabilities (2,745 )   (336 )
Deferred revenue 441     (323 )
Deferred income tax 4,757     (171 )
Net cash provided by operating activities 8,538     13,611  
Investing activities:      
Acquisition of businesses, net of cash acquired (5,731 )   (501 )
Purchases of property and equipment (493 )   (182 )
Purchase of intangible assets     (243 )
Sale of short-term investments 9,084      
Net cash provided by (used in) investing activities 2,860     (926 )
Financing activities:      
Proceeds from stock option exercises and Employee Stock Purchase Program purchases 1,825     1,584  
Repurchase of common stock (960 )   (7,691 )
Taxes paid related to net share settlement of equity awards (539 )   (558 )
Deferred debt issuance costs      
Proceeds from borrowings     10,000  
Payments on borrowings (40,000 )    
Net cash provided by (used in) financing activities (39,674 )   3,335  
Exchange rate changes effect on cash and cash equivalents 4,801     (1,021 )
Net increase (decrease) in cash and cash equivalents (23,475 )   14,999  
Cash and cash equivalents, beginning of period 103,778     81,285  
Cash and cash equivalents, end of period $ 80,303     $ 96,284  


NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
               
   Quarter Ended    Year to Date
  June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016
GAAP based results:              
Income (loss) before provision for income tax $ (6,655 )   $ 13,955     $ (6,293 )   $ 25,623  
               
Non-GAAP adjustments:              
Intangibles Amortization - Cost of revenue 1,500     604     2,500     1,205  
Intangibles Amortization - Operating expense 3,885     2,197     7,959     4,332  
Recall Accrual and Remediation Efforts (COGS) 2,381         4,659     267  
Recall Accrual and Remediation Efforts (R&D) 2,406         5,103      
Restructuring 361     1,083     593     1,118  
Litigation 750         1,336      
Direct costs of acquisitions (COGS) 2,401         4,370      
Direct costs of acquisitions (M&S) (31 )   (583 )   (36 )   (583 )
Direct costs of acquisitions (G&A) 852         913      
Direct costs of acquisitions (OI&E) 24     74     48     74  
Peloton Collection Reserve 4,058         4,058      
Discontinued product line charges (COGS) 1,684         1,684      
Discontinued product line charges (G&A) 429         429      
Non-GAAP income before provision for income tax 14,045     17,330     27,323     32,036  
               
Income tax expense, as adjusted $ 2,841     $ 4,554     $ 6,292     $ 8,129  
               
Non-GAAP net income $ 11,204     $ 12,776     $ 21,031     $ 23,907  
 Non-GAAP earnings per share:              
  Basic $ 0.34     $ 0.39     $ 0.65     $ 0.74  
  Diluted $ 0.34     $ 0.39     $ 0.64     $ 0.72  
               
 Weighted-average shares used to compute              
  Basic non-GAAP earnings per share 32,529     32,438     32,507     32,521  
  Diluted non-GAAP earnings per share 33,034     32,983     33,061     33,118  


NATUS MEDICAL INCORPORATED AND SUBSIDIARIES
RECONCILIATION OF NON-GAAP ADJUSTMENTS (unaudited)
(in thousands, except per share amounts)
               
   Quarter Ended    Year to Date
  June 30, 2017   June 30, 2016   June 30, 2017   June 30, 2016
GAAP Gross Profit 66,138     57,475     132,884     111,734  
Amortization of intangibles 1,500     604     2,500     1,205  
Acquisition charges 2,401         4,370      
Recall accrual and remediation efforts 2,381         4,659     267  
Discontinued product line charges 1,684         1,684      
Non-GAAP Gross Profit 74,104     58,079     146,097     113,206  
Non-GAAP Gross Margin 60.6 %   60.5 %   59.2 %   61.8 %
               
GAAP Operating Profit (6,277 )   13,930     (4,875 )   25,142  
Amortization of intangibles 5,385     2,801     10,459     5,537  
Recall accrual and remediation efforts 4,787         9,762     267  
Litigation 750         1,336      
Restructuring and acquisition charges 3,583     500     5,840     535  
Peloton collection reserve 4,058         4,058      
Discontinued product line charges 2,113         2,113      
Non-GAAP Operating Profit 14,399     17,231     28,693     31,481  
Non-GAAP Operating Margin 11.8 %   18.0 %   11.6 %   17.2 %
               
GAAP Provision for income tax expense (benefit) (1,621 )   3,443     (1,606 )   6,573  
Effect of accumulated change of pretax income 3,791     846     7,041     1,642  
Effect of change in annual expected tax rate 467     265     653     464  
Tax audit reserve             (550 )
Effect on acquisition cost 204         204      
Non-GAAP Income tax expense, as adjusted 2,841     4,554     6,292     8,129  
               
   Quarter Ended    Year to Date        
  September 30, 2017   December 31, 2017        
GAAP EPS Guidance $0.17 - $0.18   $0.55 - $0.60        
Amortization of Intangibles 0.17     0.69          
Restructuring 0.06     0.36          
Litigation     0.02          
Recall Accrual and Remediation Efforts     0.04          
Direct cost of acquisitions 0.03     0.22          
Peloton collection reserve     0.12          
Discontinued product line charges     0.06          
Tax effect (0.06 )   (0.36 )        
Non-GAAP EPS Guidance $0.37 - $0.38   $1.70 - $1.75        

 

Natus Medical Incorporated
                    Jonathan A. Kennedy
                    Executive Vice President and Chief Financial Officer
                    (925) 223-6700
                    InvestorRelations@Natus.com   

Primary Logo

Powered by EIN News